https://pubmed.ncbi.nlm.nih.gov/?

term=Cardiovascular+Disease+AND+CARDIOLOGY+
%5BAD%5D+AND+SINGAPORE+%5BAD%5D&format=abstract

1. Jacqueline Saw , 192

Clinical Associate Professor in the Division of Cardiology at the University of British
Columbia, Program Director for VGH Interventional Cardiology Fellowship Program
and Head for VGH Cardiology Clinical Trials Research
Division of Cardiology, Vancouver General Hospital, Vancouver, BC, Canada
jsaw@mail.ubc.ca

Dr. Jacqueline Saw is an Interventional Cardiologist at Vancouver General Hospital

(VGH), with joint appointment at St Paul’s Hospital. She is a Clinical Associate
Professor of Medicine at the University of British Columbia, and Program Director of
the Interventional Cardiology Fellowship Program at VGH.
She was awarded Canada Scholar and the Dean’s Entrance Scholarship for Natural
Sciences at Simon Fraser University, where she did her undergraduate degree. She
then obtained her medical doctorate at the University of Ottawa, where she graduated
summa cum laude. She did her residency training in Internal Medicine and
Cardiology at the University of British Columbia, and served as Chief Cardiology
Fellow. She then proceeded to Interventional Cardiology fellowship training at the
Cleveland Clinic, which encompassed carotid, peripheral and structural interventional
training. She has been an active staff with the Division of Cardiology at VGH and
joint appointment at St Paul’s Hospital since 2004. She is also a physician proctor for
left atrial appendage closure with the Amplatzer Cardiac Plug and WATCHMAN
devices.
Dr. Saw’s research interests include spontaneous coronary artery dissection (SCAD),
left atrial appendage closure, antiplatelet therapy, percutaneous coronary intervention,
carotid artery stenting, peripheral intervention and non-atherosclerotic coronary artery
disease [including SCAD and coronary fibromuscular dysplasia (FMD) in women].
She is the principal investigator of the Canadian SCAD Study, PRYME, NACAD,
SAFER-SCAD, Canadian WATCHMAN Registry, TAP-CABG, and ELAPSE
studies.

https://scadalliance.org/board/jacqueline-saw-m-d/

2. Alaide Chieffo, 288

Clinical Research Director / Interventional Cardiologist. Interventional Cardiology
Unit, San Raffaele Scientific, Interventional Cardiology Unit, IRCCS San Raffaele
Scientific Institute, Milan, Italy. chieffo.alaide@hsr.it
 Dr. Chieffo is a full-time interventional cardiologist and Director of Research at San
Raffaele Hospital in Milan Italy. She also serves as Scientific Coordinator of the
Master in Interventional Cardiology at University Vitae Salute, Milan, Italy. She is
also WIN SCAI Program Co-chair.

https://scai.org/alaide-chieffo-md-irccs-fscai

3. DENNIS T KO, 226

Director, Schulich Heart Research Program, Sunnybrook Research Institute

Senior scientist, Evaluative Clinical Sciences, Schulich Heart Research Program,
Sunnybrook Research Institute; ASSOCIATE PROFESSOR OF CARDIOLOGY,
Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto,
Toronto, Ontario, Canada; Institute of Health Policy Management and Evaluation,
University of Toronto, Toronto, Ontario, Canada; Institute of Clinical and Evaluative
Sciences, Toronto, Ontario, Canada dennis.ko@ices.on.ca

Dr. Ko received his M.D. from the University of Ottawa and completed his postgraduate
training at the Cleveland Clinic Foundation and Yale University School of Medicine. Dr. Ko
is currently an Associate Professor at the University of Toronto in the Department of
Medicine and the Institute of Health Policy, Management & Evaluation, a Senior Scientist at
the Institute for Clinical Evaluative Sciences (ICES) and the Sunnybrook Research Institute.
He works clinically as an interventional cardiologist at the Sunnybrook Health Sciences
Centre.
Dr. Ko’s research focuses on determining optimal clinical strategies and identifying
opportunities to improve the outcomes of cardiovascular conditions. These efforts are
intended to provide critical information to policy makers to improve the quality of health care
and guide decisions about the allocation of scarce health care resources.
Dr. Ko has been supported by a Canadian Institutes of Health Research (CIHR) New
Investigator Award and a Heart and Stroke of Ontario Clinician Scientist Award. He is the
principal investigator on several ongoing grants from CHIR and Heart and Stroke.
https://sunnybrook.ca/research/team/member.asp?t=11&m=99&page=178

4. Stephen E Fremes, 338

Professor, department of surgery (cardiac), University of Toronto; Scientist, Evaluative

Clinical Sciences, Schulich Heart Research Program, Sunnybrook Research Institute
Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto,
Toronto, Ontario, Canada; Institute of Health Policy Management and Evaluation,
University of Toronto, Toronto, Ontario, Canada. Electronic address:
stephen.fremes@sunnybrook.ca

Research Focus:
 Clinical studies of cardiac surgery
 The themes of Dr. Fremes' research have been myocardial protection for cardiac
surgery, arterial conduits for coronary surgery and imaging of coronary artery bypass
grafts. His methods of investigation primarily include preoperative single and
multicentre clinical trials and outcomes research. In the past five years, he has also led
investigations of transcatheter valvular surgery.

https://sunnybrook.ca/research/team/member.asp?t=10&m=66&page=527

5. CAROLYN S P LAM, 314

PROFESSOR, National Heart Centre Singapore and Duke-National University of Singapore,

Singapore; University Medical Centre Groningen, Groningen, the Netherlands. Electronic
address: carolyn.lam@duke-nus.edu.sg

Professor Carolyn Lam is a Senior Consultant from the Department of Cardiology and
Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered
the first Women’s Heart Clinic in Singapore. Academically, she serves as a tenured Full
Professor at the Duke-National University of Singapore, having also graduated from the
Standford Executive Programme in 2015, and obtained a PhD at the University Medical
Centre Groningen, the Netherlands in 2016. In the field of MedTech, Prof Lam is co-founder
of Us2.ai, an award-wining startup dedicated to the automation of the fight against heart
disease by applying artificial intelligence to echocardiography (ultrasound of the heart).

Prof Lam is a world-renowned specialist in heart failure (particularly heart failure with
preserved ejection fraction [HFpEF]). Her work in the PARAGON-HF and EMPEROR-
Preserved trials led to the first FDA-approved treatment for HFpEF and the first robustly
positive clinical outcomes trial in HFpEF to-date, respectively. She leads several
multinational global and regional clinical trials, and has received numerous prestigious
awards and global recognition for her work. Her recent appointments on the 2021 European
Society of Cardiology Heart Failure Guidelines Task Force, and as International Honorary
Fellow of the Heart Failure Society of America 2021, attest to her contributions in both
cardiology and research fields.

https://www.duke-nus.edu.sg/directory/detail/lam-su-ping-carolyn

6. Stuart A Cook, 196

PROFESSOR, Department of Cardiology, Royal Brompton Hospital, London, United
Kingdom; Department of Cardiovascular Medicine, National Heart & Lung Institute,
Imperial College, London, United Kingdom; Department of Cardiology, National
Heart Centre Singapore, Singapore. stuart.cook@imperial.ac.uk

Professor Stuart Cook is the head of the Cardiovascular Genetics and Genomics
group within Genetics & Imaging at the National Heart and Lung Institute (NHLI).
 He is a cardiologist at the National Heart Centre Singapore where he oversees the
clinical MRI service. He is the Director of the National Heart Research Institute
Singapore and Program Director of the CVMD program at Duke-NUS. He is co-
founder of Enleofen, a biotechnology company developing therapies for the treatment
of fibrotic diseases.

https://www.duke-nus.edu.sg/directory/detail/stuart-cook

7. Martin R Cowie, 286

PROF, Department of Cardiology, Royal Brompton Hospital, London, United
Kingdom; Department of Cardiovascular Medicine, National Heart & Lung Institute,
Imperial College, London, United Kingdom m.cowie@imperial.ac.uk

Martin Cowie is Professor of Cardiology (Health Services Research) and is an Honorary

Consultant Cardiologist at the Royal Brompton and Harefield NHS Foundation Trust.

After qualifying from the University of Aberdeen in 1989, Professor Cowie trained in
London in cardiology and epidemiology, undertaking a MSc in Epidemiology at the London
School of Hygiene and Tropical Medicine. His MD related to work on the epidemiology of
heart failure in the UK. After a brief period back in Scotland, he returned to Imperial College
in 2001, taking up the Chair of Cardiology (Health Services Research) at the National Heart
& Lung Institute, with his clinical practice based at the Royal Brompton Hospital in Chelsea.

He also works with the Department of Health, The National Institute for Health and Care
Excellence, the Quality Care Commission, and the Department of Transport (Medical
Advisory Panel).

A founding member and past-Chair of the British Society for Heart Failure, he has also sat on
the Board of the Heart Failure Association of the European Society of Cardiology. He is a
member of the European Society of Cardiology’s EU Affairs Committee, and sits on the
strategic Cardiovascular Roundtable of that organisation.

His major clinical and research interests are in health technology assessment and the delivery
of efficient and effective care for patients with heart failure, with a particular focus on new
technologies: diagnostics, drugs or devices.

https://www.imperial.ac.uk/people/m.cowie

8. Stephane Heymans , 241

PROFESSOR, Department of Cardiology, CARIM, Maastricht University Medical
Centre, Maastricht, the Netherlands.
s.heymans@maastrichtuniversity.nl

Stephane Heymans is Professor of Cardiomyopathies and Head of the Centre for

Heart Failure Research, Department of Cardiology, Maastricht University. He
obtained his Medical Degree from the KULeuven (Belgium) in 1995 and went on to
 get a PhD in Medical Sciences in 2000, studying the role of proteinases in acute
myocardial infarction. In 2003, He joined the Cardiology Department University
Hospital of Maastricht (The Netherlands) as an academic medical specialist and in
2006 he took over the Multidisciplinary Cardiomyopathy Program (Genetics,
Immunology, Microbiology and Pathology departments).
In 2008 he established his independent research laboratory at Cardiovascular
Research Institute Maastricht. His research interests focus on the molecular
mechanisms of heart failure, looking at the interplay between inflammatory cells,
fibroblasts and cardiomyocytes. Particular focus is on the role of non-structural matrix
proteins, matrix turnover and non-coding RNAs.
He is chair of the Strategic Board of the Cardiovascular Research Institute Maastricht
(CARIM), Maastricht University, Professor of “Inflammation and Matrix Biology in
Cardiomyopathies” at the University of Leuven and he is a board member of the ESC
Heart Failure Association, ESC Working Group of Myocardial Function, ESC Heart
Failure Association Committee on Diastolic Heart Failure and ESC Heart Failure
Association Committee on Translational Research.

https://car.mumc.maastrichtuniversity.nl/profile/s.heymans
%40maastrichtuniversity.nl

9. Petar M Seferovic, 296

PROFESSOR, Cardiology Department, Clinical Centre Serbia, Medical School,
Belgrade, Serbia.

Petar Seferovic is Vice-president of The European Society of Cardiology and President of the
Heart Failure Association of the European Society of Cardiology. He has a long standing
experience in the activities of ESC, and later was involved in Heart Failure Association
projects for almost a decade.

After completing his training and fellowship at Belgrade University School of Medicine and
Kings College Hospital in London, UK, he spent two years as a Visiting Assistant professor
in Methodist Hospital and Baylor College of Medicine, Houston, USA. Prof. Seferović was
leading the introduction of several methods of interventional cardiology and myocardial and
pericardial disease in Serbia, including percutaneous transluminal angioplasty,
endomyocardial biopsy, percutaneous pericardioscopy and pericardial biopsy. Starting mid-
90’s, he dedicated his clinical and research activity to chronic and acute heart failure. He is
full member of Serbian Academy of Sciencies and Arts and President, Heart Failure Society
of Serbia.
His research interests mainly include heart failure (acute and chronic), cardiovascular disease
(heart failure) and diabetes, as well as cardiomyopathies, myocarditis and pericardial disease.
He has been involved in numerous heart failure clinical trials as a National coordinator and
Principal investigator, member of international steering committees, endpoint committees,
and advisory boards.

https://www.tmacademy.org/hfgf-digital-forum-8th-edition/petar-seferovic/

10. Filippos Triposkiadis , 176

PROF, Department of Cardiology, Larissa University General Hospital, Larissa,
Greece. Electronic address: ftriposkiadis@gmail.com
ftriposk@med.uth.gr

Clinical activities: Invasive cardiology, heart failure, intensive care

Publications: a) Publications: 230, c) Citations: 5000. Also, editor of 3 textbooks.

Participation in scientific Societies: National: a) Hellenic Cardiological Society

(member), b) Hellenic Hypertension Society (member), c) Hellenic Society of
Atherosclerosis (member), d) Hellenic Society for the Study and Research of Heart
Failure (Vice president), Hellenic College of Cardiology (President Elect)
International: a) European Society of Cardiology (Fellow), b) Working Group on
Valvular Heart Disease of the European Society of Cardiology, c) American College
of Cardiology (Fellow), d) Heart Failure Association of the European Society of
Cardiology (Fellow).

https://esc365.escardio.org/person/29262